SPRINGFIELD, Ill. — Legislation aimed at capping the out-of-pocket costs of prescription insulin for those with state-regulated health care plans passed a House committee Tuesday with bipartisan support and a 13-2 favorable roll call.

Senate Bill 667 now awaits a vote from the full House of Representatives. If it passes, it will head to the desk of Democratic Gov. J.B. Pritzker, who has been a vocal supporter of the measure.

The bill would cap the price for a 30-day supply of insulin at $100 for people covered under certain kinds of insurance policies.

It would not limit how much drug companies can charge for insulin. Rather, it would force insurance companies that would be covered by the new law to pick up a larger share of the cost.

The bill also would not apply to plans offered by large employers that are governed by the federal Employee Retirement Income Security Act because the state cannot preempt federal law.

After an amendment, the legislation directs executive agencies to investigate why insulin prices have been rising sharply in recent years. The attorney general’s office was tasked with that investigation under a previous version of the bill.

The measure faced questioning and two “no” votes from Republicans, who suggested price caps could create higher premiums for consumers.